Corcept Therapeutics (NASDAQ: CORT) reported Q1 EPS of $0.20, $0.01 better than the analyst estimate of $0.19. Revenue for the quarter came in at $64.8 million versus the consensus estimate of $69.29 million.

For earnings history and earnings-related data on Corcept Therapeutics (CORT) click here.